SCHEMBL5552472

SCHEMBL5552472

O=C(CC(Cl)C(=O)O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.64
ALDH1A1 P00352 4/20 0.54
GSK3B P49841 2/20 0.54
MAPK1 P28482 2/20 0.54
PTPN1 P18031 2/20 0.54
TRPA1 O75762 1/20 0.54
HIF1A Q16665 1/20 0.54
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
MAPT P10636 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HPGD P15428 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
KDM4E B2RXH2 2/20 0.52
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
CES1 P23141 1/20 0.52
GAA P10253 1/20 0.51
NPC1 O15118 1/20 0.49
L3MBTL1 Q9Y468 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8534214 0.86 TSHR (0.57) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL8459143 0.84 TSHR (0.55) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL2255355 0.83 TSHR (0.63) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL5990135 0.81 TSHR (0.61) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL5313340 0.80 TSHR (0.72) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL2598225 0.79 TSHR (0.59) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL28481770 0.79 TSHR (0.59) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL5158714 0.79 TSHR (0.59) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL8898345 0.79 TSHR (0.59) TSHRALDH1A1GSK3BMAPK1PTPN1
SCHEMBL5549102 0.78 KMT2A (0.71) TSHRALDH1A1GSK3BMAPK1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513868-B1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL (TR) 2006-08-09 EP claimed
US-20070093664-A1 Process for the production of lisinopril ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) 2007-04-26 US disclosed
EP-1513868-B1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL (TR) 2006-08-09 EP disclosed
EP-1513868-B1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL (TR) 2006-08-09 EP disclosed
EP-1513868-A1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) 2005-03-16 EP disclosed
EP-1513868-A1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) 2005-03-16 EP disclosed
WO-2004000874-A1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) 2003-12-31 WO disclosed
WO-2004000874-A1 PROCESS FOR THE PRODUCTION OF LISINOPRIL EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) 2003-12-31 WO disclosed
US-3933838-A ANTIINFLAMMATORY, ANTIPYRETIC, ANALGESICS, ANTIBACTERIAL, DEPRESSANTS, ANTIULCER, ANTICOUGH INSTITUTO LUSO FARMACO D'ITALIA S.R.L. (IT) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093664-A1 Process for the production of lisinopril ACE, LOX, AGT TSHR 3587/4885ALDH1A1 53/4885GSK3B 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.